Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31404141 | 1.00 | GLS (0.54) | GLSSMN1; SMN2TDP1POLBAPEX1 | |
| SCHEMBL13296078 | 0.87 | SMN1; SMN2 (0.45) | GLSSMN1; SMN2TDP1POLBAPEX1 | |
| SCHEMBL30664932 | 0.87 | SMN1; SMN2 (0.45) | GLSSMN1; SMN2TDP1POLBAPEX1 | |
| SCHEMBL2152356 | 0.85 | GLS (0.50) | GLSTDP1POLBAPEX1RECQL | |
| SCHEMBL6282275 | 0.84 | CYP4F2 (0.44) | GLSSRD5A1SRD5A2 | |
| SCHEMBL5152840 | 0.84 | CYP4F2 (0.44) | GLSSRD5A1SRD5A2 | |
| SCHEMBL22798882 | 0.81 | GLS (0.42) | GLSHPGDSRD5A1SRD5A2AKR1B1 | |
| SCHEMBL20562936 | 0.81 | GLS (0.50) | GLSTDP1POLBAPEX1RECQL | |
| SCHEMBL15796618 | 0.81 | GLS (0.47) | GLSTDP1POLBAPEX1RECQL | |
| SCHEMBL24193319 | 0.81 | SMN1; SMN2 (0.46) | GLSSMN1; SMN2TDP1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753560-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-12-23 | — | — | EP | claimed |
| EP-4743453-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4526289-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025015178-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| WO-2023225162-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225162-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| CN-101421252-B | 2, 6-substituted-4-monosubstituted aminopyrimidines as prostaglandin D2 receptor antagonists | SANOFI AVENTIS | 2011-10-12 | — | — | CN | disclosed |
| CN-101421252-A | 2, 6-substituted-4-monosubstituted aminopyrimidines as prostaglandin D2 receptor antagonists | SANOFI AVENTIS (FR) | 2009-04-29 | — | — | CN | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| CN-101039920-A | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | AVENTIS PHARMA INC (US) | 2007-09-19 | — | — | CN | disclosed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | GLS 546/4885SMN1; SMN2 2553/4885TDP1 874/4885 |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | MAVS, IRF3, EIF2AK2 | GLS 1268/4885SMN1; SMN2 2605/4885TDP1 56/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | GLS 2738/4885SMN1; SMN2 4606/4885TDP1 2322/4885 |
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, PTGER2 | GLS 1657/4885SMN1; SMN2 1857/4885TDP1 2484/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | GLS 2971/4885SMN1; SMN2 2111/4885TDP1 3507/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | GLS 2971/4885SMN1; SMN2 2111/4885TDP1 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.